Intraperitoneal chemotherapy combined with intravenous chemotherapy after operation in the ovarian epithelial cancer
- VernacularTitle:卵巢癌术后腹腔和静脉联合化疗的可行性
- Author:
Jianlong ZHU
;
Lingda FENG
;
Lei WENG
- Publication Type:Journal Article
- Keywords:
ovarian cancer;
intraperitonal chemotherapy;
intravenous chemotherapy;
CA125
- From:
China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer. Methods:The 88 patients of ovarian cancer after cytoreductive surgery were divided into two groups A and B. A group(45 cases) received intraperitonal chemotherapy three times once a week with DDP and 5-FU plus either the MMC or AT-1258, then intravenous chemotherapy, stages Ⅰ/Ⅱ 21 cases(23.86%),stages Ⅲ/Ⅳ 24 cases(27.27%). B groups were given intravenous chemotherapy with CAP protocol once every three weeks,stage Ⅰ/Ⅱ 24 cases(27.27%),stages Ⅲ/Ⅳ 19 cases(21.59%).Results:After three or six courses of chemotherapy there was significant decrease in CA125 both Ⅰ/Ⅱ and Ⅲ/Ⅳ in A and B groups . After three courses of chemotherapy there were 34 cases((38.64%))of A groups and 19 cases(21.59%)of the B groups with CA12535 u/ml(35 cases) who were given three courses of chemotherapy after entire treatment. A and B groups in the Ⅰ/Ⅱ stages showed average survival time (35.05?0.54),(32.38?1.19) months,and in the Ⅲ/Ⅳ stages showed average survival time (31.33?1.41),(28.26?1.88) months.There was no significance (P=0.156) with three year survival rate between A and B groups in the Ⅰ/Ⅱ stages with Log Rank test. There was no significance (P=0.08) in three-year survival rate between A and B groups in the Ⅲ/Ⅳ stages with Log Rank test. There was significance in three-year survival rate between A and B with intraperitonal fluid.Conclusions:The intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer could marketly decrease CA125 than intravenous chemotherapy after three or six courses. Three-year survival ratewas significantly different between CA125 35 u/ml(35 cases) when they were given three courses of chemotherapy after entire treatment. Although the intraperitonal chemotherapy after surgery for the treatment of ovarian cancer had no significant difference between A and B groups in Ⅰ/Ⅱ and Ⅲ/Ⅳ stages with three-year survival rate , it appears longer survival time . There is significant difference with three-year survival between A and B with intraperitonal fluid. The intraperitional chemotherapy combined with intravenous chemotherapy after surgery can be used for the ovarian cancer with intraperitonal fluid and metastases.
